Skip to main navigation Skip to search Skip to main content

Digoxin-specific antibodies: a novel dosing strategy

  • Marieke A Dijkman*
  • , Femke M J Gresnigt
  • , Dylan W de Lange
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Downloads (Pure)

Abstract

Digoxin-specific antibodies (digoxin-Fabs) are of value in the treatment of a strongly suspected or a known, potentially life-threatening digoxin toxicity. These antibodies are not registered for use in Europe; therefore Dutch hospital pharmacies are not allowed to keep them in stock. In the Netherlands, digoxin-Fabs are stored in a national calamity stock of emergency medicines at the National Institute for Public Health and the Environment. In the case of a medical emergency, digoxin-Fabs are available after contact with the Dutch Poisons Information Centre. Recent studies have shown that the dose of digoxin-Fabs required to effectively treat digoxin toxicity is lower than previously thought. In this article, we present the adjusted digoxin-Fab dosing strategy currently recommended by the Dutch Poisons Information Centre ( www.vergiftigingen.info ). This new dose titration strategy is safe and effective and has a cost-saving side-effect.

Original languageEnglish
Pages (from-to)70-73
Number of pages4
JournalNetherlands Heart Journal
Volume32
Issue number2
DOIs
Publication statusPublished - Feb 2024

Keywords

  • Antidote
  • Digoxin poisoning
  • Digoxin-specific antibodies

Fingerprint

Dive into the research topics of 'Digoxin-specific antibodies: a novel dosing strategy'. Together they form a unique fingerprint.

Cite this